Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report
- 161 Downloads
Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma.
Cisplatin concentrations were determined in plasma and ultrafiltrate samples collected on each of six cycles of a monotherapy regimen, beginning with a dose of 1.6 mg/kg at 16 days of age. Pharmacokinetic data were analyzed to generate clearance (CL) and area under the curve (AUC0–∞) for each administration. Toxicity and clinical response were monitored.
The first cisplatin dose (1.6 mg/kg) resulted in an AUC0–∞ of 535 µg/mL · min, was well tolerated and associated with a good response. This AUC was, therefore, considered as an appropriate target for this patient. Increases in cisplatin CL were observed across consecutive treatment cycles, and, therefore, dose was gradually increased to finally reach 2.5 mg/kg on the sixth cycle. Treatment was well tolerated over the six courses and resulted in a good response, with the patient remaining in remission at 15 months. Cisplatin CL was significantly correlated to age (p = 0.013) and weight (p = 0.013).
Our study provides useful data on the pharmacokinetics of cisplatin monotherapy in neonates treated within the first few weeks of life. These data provide a reference point to support clinicians in determining appropriate dosing regimens for neonates and support the implementation of therapeutic drug monitoring in such challenging patients.
KeywordsCisplatin Hepatoblastoma SIOPEL Pharmacokinetics Neonate
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from the parents of the patient to take blood samples to perform individualized dosing.
- 3.Dall’Igna P, Brugieres L, Christin AS et al (2018) Hepatoblastoma in children aged less than six months at diagnosis: a report from the SIOPEL group. Pediatr Blood Cancer 65. https://www-ncbi-nlm-nih-gov.gate2.inist.fr/pubmed/28921839
- 12.Bardin C, Veal G, Paci A et al (2014) Therapeutic drug monitoring in cancer—are we missing a trick? Eur J Cancer Oxf Engl 1990 50:2005–2009Google Scholar